Loading
Thursday, October 22, 2026 · Vol. I, No. 43Independent · Canadian · Research-first
Before you compare Canadian research sourcesRun the free 10-point COA + batch audit at LynxLabs →
BPC-157 · research summary
Alternative therapies in health and medicine · 2025. Summary drawn from the study's abstract. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.
IRB-approved pilot study assessing safety of intravenous BPC-157
“This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans.”
Two healthy adults, a 58-year-old Asian male and a 68-year-old Caucasian female, who had previously received intravenous BPC-157
“Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.”
2 participants
“Baseline blood work and vital signs were obtained from 2 participants before and after each infusion.”
3 days with infusions on day 1 and day 2
“On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour.”
No measurable effects on tested biomarkers for heart, liver, kidneys, thyroid, or blood glucose
“The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels.”
No side effects were reported by participants
“The BPC-157 peptide infusion was tolerated, with no side effects reported.”
Small sample size of only two participants and need for future confirmation
“Future studies are also needed to confirm the safety of intravenous BPC-157 in humans.”
Source: PubMed 40131143 · all study summaries